Forget a Cash ISA! I’d aim to make a passive income with these 2 FTSE 100 dividend stocks

I think these two FTSE 100 (INDEXFTSE:UKX) income shares appear to offer favourable prospects when compared to a Cash ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the best returns available on a Cash ISA are currently around 1.5%, buying FTSE 100 dividend shares could prove to be a shrewd move.

In many cases, it is possible to double, or even treble, your passive income when compared to Cash ISA rates.

With interest rates set to remain at their current level, or even fall, over the next few years, now could be a good time to buy these two large-cap income shares. They appear to have sound strategies that could produce capital growth alongside their income returns.

AstraZeneca

With a 3.1% dividend yield, AstraZeneca (LSE: AZN) may not be among the highest-yielding shares in the FTSE 100. However, the pharmaceutical company’s dividend growth prospects could make it a sound income opportunity for the long run.

Its recent updates have shown that its pipeline has improved dramatically in recent years after an ambitious investment programme. This could position the company for growth in a world where demographic challenges may catalyse demand for a wide range of healthcare products and services.

AstraZeneca’s defensive business model may prove to be attractive to many investors during what is a period of significant economic and political risk.

Furthermore, with its dividend expected to be covered 1.3 times by net profit in the current year, there seems to be scope for its shareholder payouts to rise at a brisk pace. This could lead to a strong and dependable passive income stream for its investors that catalyses its share price over the long run.

British Land

Real estate investment trust (REIT) British Land (LSE: BLND) is a very different investment proposition than AstraZeneca. The property company is facing a period of disruption across much of its asset base, with demand for retail units expected to come under pressure over the medium term as online shopping becomes increasingly popular.

This could cause rents to decline, which may put the company’s dividend growth rate under a degree of pressure. However, with British Land shifting its focus away from retail and towards faster-growing areas such as flexible office space, it seems to have a sound strategy that could lead to improving financial performance in the long run.

Furthermore, investors appear to have factored in the risks facing the business. It trades on a price-to-book (P/B) ratio of just 0.6, while its dividend yield of 5.4% is among the highest yields currently available in the FTSE 100.

Certainly, British Land may prove to be a relatively risky stock to own in the short run, as it aims to transition towards assets that have greater growth potential. For long-term income investors, now could be the right time to buy a slice of the business based on its high income return and wide margin of safety. It could offer high total returns in the coming years.

Peter Stephens owns shares of AstraZeneca and British Land Co. The Motley Fool UK has recommended AstraZeneca and British Land Co. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing For Beginners

2 FTSE 100 shares that could outperform this year regardless of geopolitics

Jon Smith notes the volatile market but explains how to pick FTSE 100 shares that can be fairly insulated to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

With share prices rising, is now the time to hold off buying stocks?

Despite share prices rising, Stephen Wright thinks there are still opportunities for investors looking for stocks to consider buying.

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

6% dividend yields and a P/E below 6! Here’s a FTSE 250 bargain share to consider

I love UK shares with low earnings multiples and high dividend yields. So I'm considering buying this cheap-as-chips FTSE 250…

Read more »

A graph made of neon tubes in a room
Investing Articles

Dividends up 36% in 3 years! No wonder BAE Systems is a popular SIPP stock

Mark Hartley takes a closer look at the types of stocks that are popular in a SIPP, from mega-cap UK…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

£10,000 invested in Rolls-Royce shares at the start of the year is now worth…

Rolls-Royce shares have been the darling of the UK stock market in recent years but how have they fared in…

Read more »

Happy couple showing relief at news
Investing Articles

How to turn £10 a day in a Stocks & Shares ISA into £23,857 of passive income!

Looking for ways to make a sustained passive income? Royston Wild explains how the Stocks and Shares ISA could help…

Read more »

Close-up of British bank notes
Investing Articles

Analysts are predicting record dividends from FTSE 100 shares! What should I buy?

City forecasts suggest dividends from FTSE 100 shares will reach £88bn in 2026. But what stocks should I buy as…

Read more »

Group of friends meet up in a pub
Investing Articles

Why is everyone still selling Diageo shares?

Diageo shares remain in the doldrums. Paul Summers looks at the possible reasons why investors keep selling up and whether…

Read more »